Three active jobs. One precise topical.
A compounded spray that gives minoxidil, tretinoin, and fluocinolone three distinct jobs in one topical.
About 10 minutes. No charge unless your clinician approves.
Hair treatment is useless if the scalp cannot live with it.
Topical hair treatment has two jobs: put the active where it belongs and make the routine tolerable enough to continue. This compounded spray combines three prescription actives around that practical problem.
Minoxidil is the primary hair-growth medication in the formula. Tretinoin is included in the topical strategy around scalp delivery, while fluocinolone is a corticosteroid used to address inflammatory irritation. The combination turns what could be several separate products into one prescribed spray.
Fluocinolone is a prescription corticosteroid. Its use requires judgment about duration, frequency, scalp response, and whether the ingredient is still needed. The three-active formula makes clinical oversight essential to the plan.
Each active has a distinct job: minoxidil drives the growth pathway, tretinoin supports topical delivery, and fluocinolone calms the scalp. The spray adds targeted application with less routine clutter.
Read the evidence →For people whose scalp became part of the hair-loss problem.
Topical Treatment Keeps Irritating Your Scalp
You want to stay with a scalp-based plan, but irritation keeps making the routine harder to tolerate. You want that problem managed medically rather than accepted as the price of treatment.
You Want One Topical Step
Multiple bottles and application schedules are creating more friction than value. A compounded spray can consolidate the clinician-selected actives into one routine.
You Understand the Steroid Is Not Casual
Fluocinolone can be useful, but you do not want to self-direct a corticosteroid indefinitely. You want a clinician deciding how long it belongs in the plan.
Compounded by a licensed pharmacy and not an FDA-approved drug product. A licensed provider sets candidacy and corticosteroid duration from your full intake, and results vary.
This might not be the right fit if:
- Known hypersensitivity to minoxidil, tretinoin, or corticosteroids
- Active scalp infection or broken skin at the application site
- Cardiovascular conditions that have not been evaluated, given the minoxidil component
- Pregnancy or breastfeeding, given the tretinoin component
- A tendency toward skin thinning or reactions to topical steroids
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Minoxidil / Tretinoin / Fluocinolone Spray, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- One compounded scalp spray containing minoxidil, tretinoin, and fluocinolone
- Prepared to your individual prescription by a licensed 503A pharmacy
- Applied as directed by your provider
- Corticosteroid frequency and duration remain clinician-managed
- Response and scalp tolerance reviewed through ongoing care
Prescription issued subject to provider judgment. Results vary. Not a guarantee of outcomes.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Beauty & Skin.
Glutathione
Antioxidant defense, under clinical direction.
Compounded injectable glutathione for clinician-guided antioxidant defense beyond the supplement aisle.
GHK-Cu Copper Peptide Cream
Prescription strength. Every percentage disclosed.
Prescription-compounded GHK-Cu cream in disclosed 2% and 4% strengths, not a mystery cosmetic complex.
Minoxidil
One daily tablet. Hair treatment out of sight.
One daily oral minoxidil tablet for people who want prescription hair care without a topical routine.
What the research shows
In men, minoxidil 5 percent beat both 2 percent and placebo on hair count.
The detail
For the minoxidil component in men: in a 48-week double-blind, placebo-controlled, randomized multicenter trial in 393 men aged 18 to 49 with androgenetic alopecia, topical minoxidil 5 percent was superior to both topical minoxidil 2 percent and placebo vehicle for change in nonvellus hair count and for patient and investigator ratings of scalp coverage.1
In women, minoxidil 5 percent beat placebo on all three primary measures.
The detail
For the minoxidil component in women: in a 48-week double-blind, placebo-controlled, randomized multicenter trial in 381 women aged 18 to 49 with female pattern hair loss, topical minoxidil 5 percent was superior to placebo on all three primary measures, and topical minoxidil 2 percent was superior to placebo for hair count and investigator assessment.2
Tretinoin raised minoxidil absorption nearly threefold against a vehicle control cream.
The detail
For the tretinoin component: in a three-way randomized crossover study in 19 healthy male volunteers dosed for 20 days, applying 0.05 percent tretinoin cream once daily alongside a 2 percent topical minoxidil solution increased minoxidil absorption nearly threefold, compared with a 1.3-fold increase from a vehicle control cream, with a matching rise in transepidermal water loss.3
Once-daily minoxidil with tretinoin matched twice-daily minoxidil on hair count.
The detail
In a randomized, double-blind comparative clinical trial in 31 men aged 28 to 45 with androgenetic alopecia, a combined solution of 5 percent minoxidil and 0.01 percent tretinoin applied once daily produced increases in total and non-vellus hair count that were not statistically different from 5 percent minoxidil applied twice daily, with a similar rate of pruritus and local irritation in both groups.4
Fluocinolone oil improved scalp psoriasis signs more than its vehicle over 21 days.
The detail
For the corticosteroid component: in a randomized, double-blind, vehicle-controlled multicenter study in patients with moderate to severe scalp psoriasis, fluocinolone acetonide 0.01 percent in a topical oil produced significantly greater improvement in the signs of psoriasis over 21 days than its vehicle, confirmed by physician global assessment.5
In a chart review, a compounded minoxidil with steroid and retinoid saw higher self-reported adherence.
The detail
In a retrospective chart review of 66 Black women treated at a single academic center between 2020 and 2024 who had previously used over-the-counter minoxidil, a compounded topical minoxidil containing a steroid and a retinoid was associated with higher self-reported adherence, 84.7 percent versus 44.7 percent, fewer reported side effects, 10.6 percent versus 21.2 percent, and more patient-reported clinical improvement, 69.6 percent versus 45.0 percent. This was uncontrolled, retrospective and self-reported, and the formulation was not the one sold here.6
What it does not show
No randomized trial has tested this combination in a single topical formulation.
The detail
No trial has tested this spray. There is no randomized controlled trial of minoxidil 7 percent with tretinoin 0.025 percent and fluocinolone 0.025 percent in a single topical formulation, and no comparison of that combination against minoxidil alone or against vehicle. The spray is compounded to an individual prescription and is not an FDA-approved drug product; the studies above tested separate components at their own strengths.123456
No randomized trial shows 7 percent grows more hair than 5 percent.
The detail
The minoxidil strength here sits above the strengths that were tested. The pivotal randomized trials studied 2 percent and 5 percent topical solutions. No randomized trial establishes that 7 percent grows more hair than 5 percent, and a higher concentration means more drug available to be absorbed rather than a demonstrated gain in effect.12
Tretinoin’s documented contribution is absorption, not hair.
The detail
The documented contribution of tretinoin is pharmacokinetic rather than clinical. The human study showing a nearly threefold rise in minoxidil absorption measured absorption, not hair. The one randomized clinical comparison of minoxidil with tretinoin against minoxidil alone enrolled 31 men and found no statistically significant difference in hair counts between the two regimens.34
Fluocinolone has not been shown to grow hair.
The detail
Fluocinolone has not been shown to grow hair. Its randomized scalp evidence is in moderate to severe scalp psoriasis over 21 days, an inflammatory condition rather than pattern hair loss. No trial establishes that adding a corticosteroid to a minoxidil formulation increases hair growth, and none defines how long a corticosteroid can safely stay on the scalp in this setting.5
- Olsen EA, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical… J Am Acad Dermatol. 2002.
- Lucky AW, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil… J Am Acad Dermatol. 2004.
- Ferry JJ, Forbes KK, VanderLugt JT, Szpunar GJ. Influence of tretinoin on the percutaneous absorption of minoxidil from… Clin Pharmacol Ther. 1990.
- Shin HS, Won CH, Lee SH, Kwon OS, Kim KH, Eun HC. Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01%… Am J Clin Dermatol. 2007.
- Pauporte M, et al. Fluocinolone acetonide topical oil for scalp psoriasis. J Dermatolog Treat. 2004.
- Wyche J, Aguh C. Enhanced clinical outcomes and treatment adherence in patients using… J Clin Aesthet Dermatol. 2025.
Serious risks
- Topical minoxidil labeling directs users to stop and seek advice for chest pain, rapid heartbeat, faintness, dizziness, sudden unexplained weight gain, or swelling of the hands or feet
- Corticosteroid labeling documents folliculitis, acneiform eruptions, loss of skin color, allergic contact dermatitis, skin thinning and stretch marks
- Corticosteroid labeling warns that applying a steroid to large areas, under occlusion, or for prolonged periods can suppress the adrenal axis
Commonly reported
- Redness, itching, burning or stinging, dryness and peeling
- Sometimes contact dermatitis
- Topical minoxidil labeling documents scalp irritation and unwanted facial hair growth
- Tretinoin labeling documents peeling, dryness, burning, stinging, temporary changes in skin color and increased sensitivity to sun and wind
Most of what people report from a scalp spray like this is local. Fluocinolone is the component that has to be watched over time. That is the reason steroid frequency and duration stay with your provider, who reviews the scalp and can reduce or remove that component rather than leaving it running indefinitely. The spray is compounded to your individual prescription by a licensed 503A pharmacy and is not an FDA-approved drug product, and the minoxidil strength here is above what is sold over the counter, which is another reason a licensed clinician stays attached to the plan.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
That question is exactly why fluocinolone stays in the clinician’s lane. Corticosteroid duration and frequency should be directed and revisited by your provider rather than treated as an unlimited maintenance ingredient.
Because the spray is compounded after clinician approval, pharmacy preparation happens before fulfillment. Any time, before your renewal date. No phone calls required.
Hair treatment is evaluated over months, and response varies. Your clinician reviews the trend rather than promising a particular result by a fixed date, while also watching whether the scalp remains comfortable enough for the plan to continue.